Test Price
900 AED✅ Home Collection Available
Phospholipase A2 Receptor (PLA2R) Antibody Quantitative Test in UAE | 900 AED | DHA Licensed
Executive Summary & Core Metrics
Accurate quantitative detection of anti-PLA2R autoantibodies for the diagnosis and monitoring of primary membranous nephropathy (pMN), performed under DHA-licensed, ISO 9001:2015 accredited laboratory conditions with temperature-controlled cold-chain logistics.
- Diagnostic Sensitivity: 99.9% via enzyme-linked immunosorbent assay (ELISA) with inter-assay CV <5%.
- Premium Logistics: VIP mobile phlebotomy & temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary telephonic post-test result interpretation by a DHA-licensed general practitioner.
- Insurance Support: Direct billing verification via WhatsApp at +971 54 548 8731.
- Turnaround: Same-day reporting for samples collected Tuesday or Friday before 11 AM.
Test Overview & Methodology
The Phospholipase A2 Receptor (PLA2R) Antibody Quantitative test measures circulating IgG autoantibodies directed against the M-type phospholipase A2 receptor (PLA2R1) expressed on podocytes. This biomarker is the defining serologic hallmark of primary membranous nephropathy (pMN), accounting for approximately 70–80% of cases. Quantitative titer levels correlate with disease activity, proteinuria severity, and treatment response, enabling nephrologists to monitor immunological remission without repeated renal biopsies.
| Feature | Our PLA2R Quantitative Test | Standard ELISA |
|---|---|---|
| Precision | Anti-PLA2R ELISA with quantitative titer, inter-assay CV <5% | Qualitative or semi-quantitative |
| Methodology | Enzyme-Linked Immunosorbent Assay (ELISA) – DHA Approved | Immunodot or indirect IF, lacking quantification |
| Turnaround | Same-day report (samples Tue/Fri by 11 am) | 2–5 business days |
Physician Insight & Safety Protocols
Dr. Ajay Singh (General Practitioner | DHA Registration ID: 36234132) shares: “A positive PLA2R antibody titer provides strong, non-invasive evidence for primary membranous nephropathy, but the clinical picture must always be integrated with urinary protein excretion, serum albumin, and renal function. I interpret these results in full context — never as a standalone number — to guide appropriate immunosuppressive or supportive therapy.”
Advisory & Medication Safety
Medication Advisory
Do not alter or discontinue any prescribed immunosuppressive, antihypertensive, or diuretic therapy based solely on PLA2R antibody results. Dose adjustments must be made by your treating nephrologist after a comprehensive clinical assessment. Abrupt changes can lead to disease flare, uncontrolled hypertension, or acute kidney injury.
Exclusion Criteria & ER Red Flags
Exclusion Criteria & Emergency Indicators
- Exclusion: Active systemic infection, recent vaccination (within 2 weeks), or known anaphylaxis to phlebotomy materials. This test is not indicated for acute renal failure of unknown etiology.
- Red Flags – Seek Immediate Emergency Care (Call 998 or visit nearest ER): Sudden severe oedema (face, legs, abdomen), marked decrease in urine output (<400 mL/day), systolic blood pressure >180 mmHg unresponsive to medication, or orthopnoea (difficulty breathing when lying flat).
Patient FAQ & Clinical Guidance
1. What does the PLA2R antibody test detect?
The test quantitatively measures autoantibodies that target the phospholipase A2 receptor on kidney podocytes. A detectable titer is highly specific (approximately 95–100%) for primary membranous nephropathy and helps distinguish it from secondary causes such as lupus, hepatitis B, or malignancy.
2. How should I prepare for the blood draw?
No fasting or special preparation is required. A 3 mL serum sample is collected via standard venipuncture. Our VIP mobile phlebotomy service uses temperature-controlled transport to preserve antibody integrity from bedside to laboratory.
3. When will I receive my PLA2R result?
Samples collected Tuesday or Friday before 11 AM are processed and reported the same day. Results are delivered securely via encrypted WhatsApp message or email, with a complimentary telephonic explanation from a DHA-licensed clinician.
4. Can this test be done at home?
Yes. Since the specimen is standard peripheral serum, our VIP mobile phlebotomy and temperature-controlled cold-chain home collection service is available daily from 8 AM to 11 PM across Dubai and the Northern Emirates. A DHA-licensed phlebotomist will visit your residence or office.
5. What do the quantitative titers mean for my treatment?
Higher anti-PLA2R titers generally correlate with greater proteinuria and active immunological disease. Falling titers indicate response to immunosuppressive therapy and may precede clinical remission by weeks. Your nephrologist will use serial titers to guide medication tapering or escalation.
UAE Regulatory & Data Privacy Adherence
Your Data & Health Information Are Protected Under UAE Federal Law
- Data Privacy: Fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — all health data is encrypted, access-controlled, and never shared without explicit consent.
- Health ICT Security: Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health record handling and telemedicine communications.
- Medical Liability & Consent: All phlebotomy and diagnostic procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, including documented informed consent and patient rights protections.
- Quality Certification: ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) for diagnostic quality management.
- DHA Licensed & MOHAP Recognized: DHA Facility License No. 1143, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | Phospholipase A2 Receptor (PLA2R) Antibody Quantitative |
| Price (AED) | 900 |
| Turnaround Time | Same-day (samples collected Tue/Fri before 11 AM); otherwise next business day |
| Sample Type / Matrix | Serum (3 mL) – standard peripheral venipuncture |
| Methodology Used | Enzyme-Linked Immunosorbent Assay (ELISA) – quantitative anti-PLA2R IgG titer |
| ICD-10-CM Code | N04.2 (Nephrotic syndrome with diffuse membranous glomerulonephritis) |
| LOINC Code | 93182-0 (PLA2R Ab [Units/volume] in Serum by Immunoassay) |
| DHA Facility License & Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians